medigraphic.com
ISSN 2992-8559 (Digital)
ISSN 1405-0625 (Impreso)

2016, Número 3

<< Anterior Siguiente >>

Cir Plast 2016; 26 (3)


Manejo prequirúrgico de trauma antiguo del tendón flexor con aplicación de toxina botulínica

Flores HU, Villarreal SJL, Hernández PS, Magallanes OJJ, Arellano AJ

Idioma: Español
Referencias bibliográficas: 43
Paginas: 140-145
Archivo PDF: 311.63 Kb.


RESUMEN

Las lesiones antiguas de tendones flexores representan un reto para el cirujano reconstructivo, tanto para la realización del procedimiento reconstructivo, como en el manejo postquirúrgico. En el presente estudio se propone la utilización de toxina botulínica tipo A en el manejo prequirúrgico de pacientes con trauma antiguo de tendones flexores, aplicándoseles en el grupo muscular afectado una semana antes del procedimiento quirúrgico, realizando la reconstrucción con injerto tendinoso e inicio inmediato de la rehabilitación. Se realizó el estudio en siete pacientes con tiempo de evolución de la lesión tendinosa de ocho meses en promedio. Se utilizó injerto tendinoso en todos los casos, con reconstrucción de poleas e inicio temprano de rehabilitación. No hubo complicaciones, ni recidivas de la ruptura. Concluimos que el uso de toxina botulínica presenta beneficios en la reconstrucción tendinosa flexora antigua y su rehabilitación postquirúrgica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Boyer MI, Strickland JW, Engles D, Sachar K, Leversedge FJ. Flexor tendon repair and rehabilitation: state of the art in 2002. Instr Course Lect 2003; 52: 137-161.

  2. Chow JA, Thomes LJ, Dovelle S, Monsivais J, Milnor WH, Jackson JP. Controlled motion rehabilitation after flexor tendon repair and grafting. A multi-centre study. J Bone Joint Surg Br 1988; 70 (4): 591-595.

  3. Duran RJ, Houser RG. Controlled passive motion following flexor tendon repair in zones II and III. In: AAOS symposium on tendon surgery of the hand. St Louis: CV Mosby; 1975, pp. 105-114.

  4. Elliot D, Moiemen NS, Flemming AF, Harris SB, Foster AJ. The rupture rate of acute flexor tendon repairs mobilized by the controlled active motion regimen. J Hand Surg Br 1994; 19 (5): 607-612.

  5. Gault DT. A review of repaired flexor tendons. J Hand Surg Br 1987; 12 (3): 321-325.

  6. Lister GD, Kleinert HE, Kutz JE, Atasoy E. Primary flexor tendon repair followed by immediate controlled mobilization. J Hand Surg Am 1977; 2 (6): 441-451.

  7. May EJ, Silfverskiöld KL, Sollerman CJ. Controlled mobilization after flexor tendon repair in zone II: a prospective comparison of three methods. J Hand Surg Am 1992; 17 (5): 942-952.

  8. Silfverskiöld KL, May EJ. Flexor tendon repair in zone II with a new suture technique and an early mobilization program combining passive and active flexion. J Hand Surg Am 1994; 19 (1): 53-60.

  9. Small JO, Brennen MD, Colville J. Early active mobilisation following flexor tendon repair in zone 2. J Hand Surg Br 1989; 14 (4): 383-391.

  10. Strickland JW, Glogovac SV. Digital function following flexor tendon repair in Zone II: A comparison of immobilization and controlled passive motion techniques. J Hand Surg Am 1980; 5 (6): 537-543.

  11. Takai S, Woo SL, Horibe S, Tung DK, Gelberman RH. The effects of frequency and duration of controlled passive mobilization on tendon healing. J Orthop Res 1991; 9 (5): 705-713.

  12. Aoki M, Kubota H, Pruitt DL, Manske PR. Biomechanical and histologic characteristics of canine flexor tendon repair using early postoperative mobilization. J Hand Surg Am 1997; 22 (1): 107-114.

  13. Ejeskär A. Flexor tendon repair in no-man´s-land: Results of primary repair with controlled mobilization. J Hand Surg Am 1984; 9 (2): 171-177.

  14. Gelberman RH, Botte MJ, Spiegleman JJ, Akesson WH. The excursion and deformation of repaired flexor tendons treated with protected early motion. J Hand Surg Am 1986; 11 (1): 106-110.

  15. Horii E, Lin GT, Cooney WP, Linscheid RL, An KN. Comparative flexor tendon excursion after passive mobilization: an in vitro study. J Hand Surg Am 1992; 17 (3): 559-566.

  16. Kubota H, Manske PR, Aoki M, Pruitt DL, Larson BJ. Effect of motion and tension on injured flexor tendons in chickens. J Hand Surg Am 1996; 21 (3): 456-463.

  17. Pruitt DL, Manske PR, Fink B. Cyclic stress analysis of flexor tendon repair. J Hand Surg Am 1991; 16 (4): 701-707.

  18. Pruitt DL, Tanaka H, Aoki M, Manske PR. Cyclic stress after in vivo healing of canine flexor tendon lacerations. J Hand Surg Am 1996; 21 (6): 974-977.

  19. Tananka H, Manske PR, Pruitt DL, Larson BJ. Effect of cyclic tension on lacerated flexor tendons in vitro. J Hand Surg Am 1995; 20 (3): 467-473.

  20. Wada A, Kubota H, Akiyama T, Hatanaka H, Miura H, Iwamoto Y. Effect of absorbable polidioxanona flexor tendon repair and restricted active mobilization in a canine model. J Hand Surg Am 2001; 26 (3): 398-406.

  21. Schaffner W. Clostridium botulinum. In: Mandell GL, Bennett JE, Dolin R editors. Mandell, Douglas & Bennett’s. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone; 1990, pp. 1847-1850.

  22. Hanchanale VS, Rao AR, Martin FL, Matanhelia SS. The unusual history and the urological applications of botulinum neurotoxin. Urol Int 2010; 85 (2): 125-130.

  23. Singh BR, Li B, Read D. Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison? Toxicon 1995; 33 (12): 1541-1547.

  24. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285 (8): 1059-1070.

  25. Huttner WB. Cell biology. Snappy exocytoxins. Nature 1993; 365 (6442): 104-105.

  26. De Camilli P. Exocytosis goes with a SNAP. Nature 1993; 364 (6436): 387-388.

  27. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000; 82 (5): 427-446.

  28. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986; 103 (2): 521-534.

  29. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986; 103 (2): 535-544.

  30. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6: S146-S168.

  31. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999; 354 (1381): 259-268.

  32. Söllner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 1993; 362 (6418): 318-324.

  33. Arnon SS. Clinical botulism. In: Brin MF, Jankovic J, Hallet M editors. Scientific and terapeuthic aspects of botulium toxin. Philadelphia: Lippincott Williams & Wilkins; 2002, pp. 145-150.

  34. Mezaki T, Kaji R, Kohara N, Kimura J. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulium toxin injection. Neurology 1996; 46 (3): 845-846.

  35. Schulte-Mattler WJ, Martinez-Castrillo JC. Botulium toxin therapy of migraine and tension-type headache: comparing different botulium toxin preparations. Eur J Neurol 2006; 13 Suppl 1: 51-54.

  36. US Food and Drug Administration, FDA approve Botox to treat specific form of urinary incontinence. 2011. [25/may/2014] Available in: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269509.htm.

  37. Placzek R, Drescher W, Deuretzbacher G, Hempfing A, Meiss AL. Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am 2007; 89 (2): 255-260.

  38. Shen J, Ma J, Lee C, Smith BP, Smith TL, Tan KH et al. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats. J Orthop Res 2006; 24 (5): 1128-1135.

  39. De Aguiar G, Chait LA, Schultz D, Bleloch S, Theron A, Snijman CN et al. Chemoprotection of flexor tendon repairs using botulinum toxin. Plast Reconstr Surg 2009; 124 (1): 201-209.

  40. Ma J, Shen J, Smith BP, Ritting A, Smith TL, Koman LA. Bioprotection of tendon repair: adjunctive use of botulinum toxin A in Achilles tendon repair in the rat. J Bone Joint Surg Am 2007; 89 (10): 2241-2249.

  41. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347 (6): 395-400.

  42. Tüzüner S, Balci N, Ozkaynak S. Results of zone II flexor tendon repair in children younger than age 6 Years: botulinum toxin type A administration eased cooperation during the rehabilitation and improved outcome. J Ped Orthop 2004; 24 (6): 629-633.

  43. Wallen M, O’Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil 2007; 88 (1): 1-10.




2020     |     www.medigraphic.com